Mazdutide: First phase 3 GLP1/glucagon dual agonist weight management results
Failed to add items
Add to Cart failed.
Add to Wish List failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
Mazdutide: First phase 3 GLP1/glucagon dual agonist weight management results
-
Narrated by:
-
By:
About this listen
Could GLP1 and glucagon work together to provide weight loss benefits and improvement to metabolic and liver health? Find out about the results of the first phase 3 study of a dual GLP1/glucagon receptor agonist (mazdutide) here!
Learn more: https://drsue.ca/2025/06/mazdutide-first-phase-3-glp1-glucagon-dual-agonist-weight-management-results/
Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.